

Financial highlights

Excellent results in a transformational year

We continue to extend the platform to achieve our aspirational target of mid-teen revenue growth between 2009 and 2015.


Core product sales (\$'M)

up **25%**

Core products represent Shire's products excluding ADDERALL XR


- Our core products are the foundation of our future growth.
- This is one of our most significant Key Performance Indicators ('KPIs').

Total revenue (\$'M)




- In the year in which our historically largest drug, the blockbuster ADDERALL XR, faced generic competition, our total revenues of \$3 billion in 2009 were in line with the \$3 billion we recorded in 2008.

Year-on-year product growth (\$'M)



- Growth is broadly based across the core portfolio.

Core product sales growth (excluding ADDERALL XR)



CAGR = 35% Period Q1 2007—Q4 2009

— Our core products are now driving Shire’s growth.

Revenue from ex-US markets* (%)



— We have a clear objective to grow our business internationally and our KPIs for this is the percentage of sales generated outside the US.

— Our business is becoming increasingly international.

*Net product sales from geographic markets outside of the US

EBITDA (\$'M) (Earnings Before Interest Tax Depreciation and Amortization)




— Our KPIs for profitability and a key driver of our Return on Invested Capital (‘ROIC’) is the growth of EBITDA.

— We delivered a strong EBITDA and earnings performance despite the loss of ADDERALL XR.

EBITDA is a Non GAAP measure

2009 cashflow (\$'M)



— Our strong cash generation has supported continued investment in our business.

Cash generation is a Non GAAP measure